Advertisement

Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial

      Highlights

      • Liraglutide combined with metformin improved the atherogenic LDL lipid profile.
      • The most atherogenic subfraction LDL5 is primarily reduced.
      • The combination improved CRP, but had no effect on TNF-α.

      Abstract

      Background and aims

      Atherosclerosis in obesity and type 2 diabetes (T2DM) is associated with low-grade inflammation (LGI) and dyslipidemia, where especially small, dense lipoprotein particles are atherogenic. The glucagon-like peptide-1 receptor agonist, liraglutide, reduces cardiovascular events by poorly understood mechanisms. We investigated the effect of liraglutide combined with metformin on LGI and lipoprotein density profiles in patients with stable coronary artery disease (CAD) and newly diagnosed T2DM.

      Methods

      We conducted a randomized, double-blind, placebo-controlled, cross-over trial over a 12 + 12-week period, with ≥2-week wash-out. Intervention: liraglutide/metformin vs. placebo/metformin. Lipoproteins were separated by continuous density gradient ultracentrifugation, and LDL divided into five subfractions between 226 and 270 Å, considering particle size ≤255 Å as the atherogenic pattern. Plasma C-reactive protein and tumor necrosis factor-α were assessed by the enzyme-linked immunosorbent-assay.

      Results

      28 out of 41 randomized patients completed all visits. Intention-to-treat analysis was performed but one patient had statin dosage and was excluded from the analysis. 95% of the patients were on statin therapy. Overall, liraglutide did not affect lipid subfractions or markers of LGI compared to placebo. The combination of liraglutide and metformin reduced the total LDL subfractions, primarily by reducing the most atherogenic subfraction LDL5, and reduced CRP but not TNF-α. Explorative analyses suggested that the subfraction LDL5 during the wash-out period rebounded significantly at least in a per-protocol analysis of the sub-group of patients starting the liraglutide therapy.

      Conclusions

      In patients with CAD and newly diagnosed T2DM on stable statin therapy, liraglutide combined with metformin may improve the atherogenic LDL lipid profile and CRP.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • The Emerging Risk Factors Collaboration
        Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
        Lancet. 2010; 375: 2215-2222https://doi.org/10.1016/S0140-6736(10)60484-9
        • Beckman J.A.
        • Creager M.A.
        • Libby P.
        Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.
        J. Am. Med. Assoc. 2002; 287: 2570-2581
        • Boden G.
        Pathogenesis of type 2 diabetes. Insulin resistance.
        Endocrinol Metab. Clin. N. Am. 2001; 30 (v): 801-815
        http://www.ncbi.nlm.nih.gov/pubmed/11727400
        Date accessed: April 10, 2014
        • Hajer G.R.
        • Van Haeften T.W.
        • Visseren F.L.J.
        Adipose tissue dysfunction in obesity, diabetes, and vascular diseases.
        Eur. Heart J. 2008; 29: 2959-2971https://doi.org/10.1093/eurheartj/ehn387
        • National Cholesterol Education Program
        Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II).
        Circulation. 1994; 89: 1333-1445
        • Williams P.T.
        • Zhao X.-Q.
        • Marcovina S.M.
        • Brown B.G.
        • Krauss R.M.
        Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).
        PLoS One. 2013; 8e56782https://doi.org/10.1371/journal.pone.0056782
        • Jellinger P.S.
        • Handelsman Y.
        • Rosenblit P.D.
        • et al.
        American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis.
        Endocr. Pract. February 2017; https://doi.org/10.4158/EP171764.GL
        • Lamarche B.
        • Tchernof A.
        • Moorjani S.
        • et al.
        Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study.
        Circulation. 1997; 95: 69-75
        • Pascot A.
        • Lemieux I.
        • Prud’homme D.
        • et al.
        Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity.
        J. Lipid Res. 2001; 42: 2007-2014
        • Otvos J.D.
        • Jeyarajah E.J.
        • Cromwell W.C.
        Measurement issues related to lipoprotein heterogeneity.
        Am. J. Cardiol. 2002; 90: 22i-29i
        • Ellington A.A.
        • Kullo I.J.
        Atherogenic lipoprotein subprofiling.
        Adv. Clin. Chem. 2008; 46: 295-317
        • Anabtawi A.
        • Miles J.M.
        Metformin: nonglycemic effects and potential novel indications.
        Endocr. Pract. 2016; 22: 999-1007https://doi.org/10.4158/EP151145.RA
        • Marso S.P.
        • Daniels G.H.
        • Brown-Frandsen K.
        • et al.
        Liraglutide and cardiovascular outcomes in type 2 diabetes.
        N. Engl. J. Med. 2016; 375: 311-322https://doi.org/10.1056/NEJMoa1603827
        • Sun F.
        • Wu S.
        • Wang J.
        • et al.
        Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.
        Clin. Ther. 2015; 37: 225-241https://doi.org/10.1016/j.clinthera.2014.11.008
        • Russo G.T.
        • Labate A.M.
        • Giandalia A.
        • et al.
        Twelve-month treatment with liraglutide ameliorates visceral adiposity index and common cardiovascular risk factors in type 2 diabetes outpatients.
        J. Endocrinol. Investig. 2015; 38: 81-89https://doi.org/10.1007/s40618-014-0163-9
        • Matikainen N.
        • Söderlund S.
        • Björnson E.
        • et al.
        Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study.
        Diabetes Obes. Metab. 2018; (June 2018): 84-94https://doi.org/10.1111/dom.13487
        • Hansson G.K.
        Inflammation, atherosclerosis, and coronary artery disease.
        N. Engl. J. Med. 2005; 352: 1685-1695https://doi.org/10.1056/NEJMra043430
        • Verhagen S.N.
        • Wassink A.M.J.
        • Van der Graaf Y.
        • Visseren F.L.J.
        C-reactive protein and incident diabetes in patients with arterial disease.
        Eur. J. Clin. Investig. 2013; 43: 1052-1059https://doi.org/10.1111/eci.12142
        • Sabatine M.S.
        • Morrow D.A.
        • Jablonski K.A.
        • et al.
        Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
        Circulation. 2007; 115: 1528-1536https://doi.org/10.1161/circulationaha.106.649939
        • Ridker P.M.
        • Rifai N.
        • Pfeffer M.
        • Sacks F.
        • Lepage S.
        • Braunwald E.
        Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction.
        Circulation. 2000; 101: 2149-2153
        • Varanasi A.
        • Patel P.
        • Makdissi A.
        • Dhindsa S.
        • Chaudhuri A.
        • Dandona P.
        Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.
        Endocr. Pract. 2012; 18: 140-145https://doi.org/10.4158/EP11169.OR
        • Haugaard S.B.
        • Andersen O.
        • Pedersen S.B.
        • et al.
        Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy.
        Metabolism. 2006; 55: 175-182https://doi.org/10.1016/j.metabol.2005.08.018
        • von Scholten B.J.
        • Persson F.
        • Rosenlund S.
        • et al.
        Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
        Diabetes Obes. Metab. 2017; 19: 901-905https://doi.org/10.1111/dom.12884
        • Díaz-Soto G.
        • De Luis D.A.
        • Conde-Vicente R.
        • Izaola-Jauregui O.
        • Ramos C.
        • Romero E.
        Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
        Diabetes Res. Clin. Pract. 2014; 104: 92-96https://doi.org/10.1016/j.diabres.2014.01.019
        • Anholm C.
        • Kumarathurai P.
        • Klit M.S.
        • et al.
        Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.
        BMJ Open. 2014; 4 (e005942-e005942)https://doi.org/10.1136/bmjopen-2014-005942
        • Diabetes D.O.F.
        Diagnosis and classification of diabetes mellitus.
        Diabetes Care. 2013; 36 (S67-74)https://doi.org/10.2337/dc13-S067
        • Pedersen L.R.
        • Olsen R.H.
        • Anholm C.
        • et al.
        Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary , overweight population with stable coronary artery disease : a randomized trial.
        Atherosclerosis. 2016; 246: 221-228https://doi.org/10.1016/j.atherosclerosis.2016.01.001
        • Blake G.J.
        • Otvos J.D.
        • Rifai N.
        • Ridker P.M.
        Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women.
        Circulation. 2002; 106: 1930-1937
        • Albers J.J.
        • Lodge M.S.
        • Curtiss L.K.
        Evaluation of a monoclonal antibody-based enzyme-linked immunosorbent assay as a candidate reference method for the measurement of apolipoprotein B-100.
        J. Lipid Res. 1989; 30: 1445-1458
        • Kronenberg F.
        • Lobentanz E.M.
        • König P.
        • Utermann G.
        • Dieplinger H.
        Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides.
        J. Lipid Res. 1994; 35: 1318-1328
        • Anholm C.
        • Kumarathurai P.
        • Pedersen L.R.
        • et al.
        Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
        Diabetes Obes. Metab. 2017; 19: 850-857https://doi.org/10.1111/dom.12891
        • Siri-Tarino P.W.
        • Williams P.T.
        • Fernstrom H.S.
        • Rawlings R.S.
        • Krauss R.M.
        Reversal of small, dense LDL subclass phenotype by normalization of adiposity.
        Obesity. 2009; 17: 1768-1775https://doi.org/10.1038/oby.2009.146
        • Kumarathurai P.
        • Anholm C.
        • Nielsen O.W.
        • et al.
        Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.
        Cardiovasc. Diabetol. 2016; 15: 105https://doi.org/10.1186/s12933-016-0425-2
        • Rizzo M.
        • Rizvi A.A.
        • Patti A.M.
        • et al.
        Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
        Cardiovasc. Diabetol. 2016; 15: 162https://doi.org/10.1186/s12933-016-0480-8
        • Engelbrechtsen L.
        • Lundgren J.
        • Wewer Albrechtsen N.J.
        • et al.
        Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.
        Obes. Sci. Pract. 2017; 3: 425-433https://doi.org/10.1002/osp4.133
        • Goldberg R.
        • Temprosa M.
        • Otvos J.
        • et al.
        Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program.
        J. Clin. Endocrinol. Metab. 2013; 98: 3989-3998https://doi.org/10.1210/jc.2013-1452
        • Zinman B.
        • Gerich J.
        • Buse J.B.
        • et al.
        Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
        Diabetes Care. 2009; 32: 1224-1230https://doi.org/10.2337/dc08-2124
        • Buse J.B.
        • Rosenstock J.
        • Sesti G.
        • et al.
        Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
        Lancet. 2009; 374: 39-47https://doi.org/10.1016/S0140-6736(09)60659-0
        • Rizzo M.
        • Berneis K.
        Low-density lipoprotein size and cardiovascular risk assessment.
        QJM - Mon. J. Assoc. Phys. 2006; 99: 1-14https://doi.org/10.1093/qjmed/hci154
        • Park K.
        • Steffes M.
        • Lee D.H.
        • Himes J.H.
        • Jacobs D.R.
        Association of inflammation with worsening HOMA-insulin resistance.
        Diabetologia. 2009; 52: 2337-2344https://doi.org/10.1007/s00125-009-1486-5
        • Deacon C.F.
        • Marx N.
        Potential cardiovascular effects of incretin-based therapies.
        Expert Rev. Cardiovasc Ther. 2012; 10: 337-351https://doi.org/10.1586/erc.12.5
        • Santilli F.
        • Simeone P.G.
        • Guagnano M.T.
        • et al.
        Effects of liraglutide on weight loss, fat distribution, and β-cell function in obese subjects with prediabetes or early type 2 diabetes.
        Diabetes Care. 2017; (Epub): 1-9https://doi.org/10.2337/dc17-0589
        • Ostawal A.
        • Mocevic E.
        • Kragh N.
        • Xu W.
        Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review.
        Diabetes Ther. 2016; 7: 411-438https://doi.org/10.1007/s13300-016-0180-0
        • Feher M.
        • Vega-Hernandez G.
        • Mocevic E.
        • et al.
        Effectiveness of liraglutide and lixisenatide in the treatment of type 2 diabetes: real-world evidence from the health improvement network (THIN) database in the United Kingdom.
        Diabetes Ther. 2017; 8: 417-431https://doi.org/10.1007/s13300-017-0241-z
        • Blonde L.
        • Russell-Jones D.
        The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.
        Diabetes Obes. Metab. 2009; 11: 26-34https://doi.org/10.1111/j.1463-1326.2009.01075.x
        • Overbeek J.A.
        • Heintjes E.M.
        • Huisman E.L.
        • et al.
        Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: evidence of improved glycaemic and weight control in obese people with type 2 diabetes.
        Diabetes Obes. Metab. 2018; 20: 2093-2102https://doi.org/10.1111/dom.13335
        • Russell-Jones D.
        • Vaag a
        • Schmitz O.
        • et al.
        Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
        Diabetologia. 2009; 52: 2046-2055https://doi.org/10.1007/s00125-009-1472-y
        • Nauck M.
        • Frid A.
        • Hermansen K.
        • et al.
        Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
        Diabetes Care. 2009; 32: 84-90https://doi.org/10.2337/dc08-1355